Form 4: Spruce Biosciences Reprices Director Stock Options

Spruce Biosciences has repriced stock options for Director Daniel K. Spiegelman and other eligible personnel, adjusting exercise prices to $104.13 per share following a reverse stock split.

Summary

• Spruce Biosciences, Inc. completed a 1-for-75 reverse stock split effective August 4, 2025, combining every seventy-five shares of common stock into one share.
• In connection with the reverse split, stock options to purchase 75 shares were combined into options to purchase one share, and their exercise prices were multiplied by seventy-five.
• A one-time stock option repricing was effective on December 11, 2025, for options with exercise prices of $106.09 per share or greater.
• The repricing applies to employees and directors, including Daniel K. Spiegelman, who remained in continuous service with the company as of the repricing date.
• The exercise price of the repriced options was amended to $104.13 per share, which was the thirty-day trailing volume-weighted average price (VWAP) on the Nasdaq Capital Market on the repricing date.
• If a repriced option is exercised before the end of a one-year retention period (which may be shorter in certain circumstances), the optionholder will be required to pay the original exercise price per share.
• No other changes were made to the repriced options, including vesting schedules, expiration dates, or the number of shares underlying them.

Sentiment

Score: 3

Explanation: The repricing of options, while beneficial for incentivizing management, typically follows significant stock price declines and a reverse stock split, indicating underlying challenges. This suggests a generally negative sentiment regarding past performance, though the action itself is a corrective measure.

Positives

• The option repricing re-incentivizes directors and employees, including Daniel K. Spiegelman, by lowering the exercise price of previously underwater options.
• The new exercise price of $104.13 per share aligns with the recent 30-day trailing VWAP, making the options more attractive and potentially restoring their value as a retention tool.

Negatives

• The need for a reverse stock split and option repricing often indicates significant past underperformance of the company's stock price.
• The retention period requiring payment of the original exercise price if options are exercised early adds a condition that could complicate immediate liquidity for option holders.
• The repricing could be viewed negatively by existing shareholders due to potential future dilution if the repriced options are exercised, and it highlights past value destruction.

Risks

• The reverse stock split may not improve the company's stock price or liquidity in the long term, and could be perceived negatively by the market.
• The repricing of options, while intended to re-incentivize, could lead to increased shareholder dilution if the stock price recovers and options are exercised.
• The one-year retention period for repriced options introduces a condition that could affect the immediate value and flexibility for option holders.

Future Outlook

The option repricing is intended to re-incentivize key personnel, including directors, by making their equity awards more valuable. This suggests a strategic focus on retaining talent and aligning their interests with future company performance, particularly over the one-year retention period.

Management Comments

• The company effected a reverse stock split to adjust its capital structure.
• A one-time stock option repricing was implemented to re-align incentives for employees and directors with continuous service.
• The repriced options' exercise price was set to the 30-day trailing volume-weighted average price to reflect current market conditions.

Industry Context

Option repricing and reverse stock splits are common corporate actions in the biotechnology and growth sectors, particularly when companies experience significant stock price declines. Repricing aims to restore the incentive value of equity compensation, which can become 'underwater' (exercise price higher than market price), thereby helping to retain key talent. Reverse splits are often used to increase share price to meet exchange listing requirements or improve market perception, though they do not change a company's fundamental value.

Comparison to Industry Standards

• Option repricing is a recognized, albeit sometimes controversial, practice in industries like biotech where stock volatility is high and talent retention is critical. Companies such as Athersys (ATHX) and Sorrento Therapeutics (SRNE) have also undertaken similar repricing initiatives following periods of stock underperformance to re-motivate employees.
• Reverse stock splits are also a common mechanism, particularly for smaller cap or development-stage biotech companies, to maintain compliance with exchange minimum bid price requirements. For example, companies like Sesen Bio (SESN) and Evoke Pharma (EVOK) have executed reverse splits to avoid delisting and improve stock marketability.

Corporate Governance

Related Party Transactions

• The stock option repricing directly benefits directors and employees, including Daniel K. Spiegelman, who is a director of the company. This constitutes a transaction with related parties as it alters the terms of their compensation.

Stakeholder Impact

• Shareholders: May experience potential future dilution if repriced options are exercised, but could benefit from re-motivated management. The reverse split reduces the number of outstanding shares, which can impact liquidity and perception.
• Employees and Directors: Directly benefit from the lower exercise prices of their stock options, which restores the incentive value of their equity compensation and enhances retention.

Next Steps

• Optionholders, including Director Spiegelman, will continue to hold their repriced options, subject to the one-year retention period for exercising at the new price.
• The company will continue operations with the adjusted capital structure following the reverse stock split.

Key Dates

Recommendation

The repricing of stock options and the preceding reverse stock split are corrective actions often taken by companies facing significant stock price challenges. While the repricing aims to re-incentivize management, it also highlights past underperformance. Investors should hold to observe the impact of these changes on operational performance and future strategic direction, as these actions alone do not fundamentally alter the company's business prospects.

Keywords

Spruce Biosciences, SPRB, stock option repricing, reverse stock split, Form 4, director compensation, equity compensation, insider transaction, corporate governance